SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    IARC. GLOBOCAN 2000: cancer incidence, mortality and prevalence worldwide, IARC CancerBase. No. 5. Lyon: IARC, 2001.
  • 2
    Stewart BW, Kleihues P. World cancer report. Lyon: IARC, 2003.
  • 3
    Hsing AW, Tsao L, Devesa SS. International trends and patterns of prostate cancer incidence and mortality. Int J Cancer 2000; 85: 607.
  • 4
    Veltri RW, Miller MC, O'Dowd G J, Partin AW. Impact of age on total and complexed prostate-specific antigen cutoffs in a contemporary referral series of men with prostate cancer. Urology 2002; 60: 4752.
  • 5
    Malins DC, Johnson PM, Barker EA, Polissar NL, Wheeler TM, Anderson KM. Cancer-related changes in prostate DNA as men age and early identification of metastasis in primary prostate tumors. Proc Natl Acad Sci USA 2003; 100: 54016.
  • 6
    Whittemore AS, Kolonel LN, Wu AH, John EM, Gallagher RP, Howe GR, Burch JD, Hankin J, Dreon DM, West DW. Prostate cancer in relation to diet, physical activity, and body size in blacks, whites, and Asians in the United States and Canada. J Natl Cancer Inst 1995; 87: 65261.
  • 7
    Adlercreutz H. Phyto-oestrogens and cancer. Lancet Oncol 2002; 3: 36473.
  • 8
    Gu F, Kong X, Shan G, Den F, Wang X, Xia T, Ma W. Study on the incidence of hyperplasia and adenocarcinoma of prostate in China. China Tumour 1997; 6: 19.
  • 9
    Debes JD, Tindall DJ. The role of androgens and the androgen receptor in prostate cancer. Cancer Lett 2002; 187: 17.
  • 10
    Whittemore AS, Wu AH, Kolonel LN, John EM, Gallagher RP, Howe GR, West DW, Teh CZ, Stamey T. Family history and prostate cancer risk in black, white, and Asian men in the United States and Canada. Am J Epidemiol 1995; 141: 73240.
  • 11
    Norrish AE, McRae CU, Cohen RJ, Jackson RT. A population-based study of clinical and pathological prognostic characteristics of men with familial and sporadic prostate cancer. BJU Int 1999; 84: 3115.
  • 12
    Hsing AW, Wang RT, Gu FL, Lee M, Wang T, Leng TJ, Spitz M, Blot WJ. Vasectomy and prostate cancer risk in China. Cancer Epidemiol Biomarkers Prev 1994; 3: 2858.
  • 13
    Kattan MW, Potters L, Blasko JC, Beyer DC, Fearn P, Cavanagh W, Leibel S, Scardino PT. Pretreatment nomogram for predicting freedom from recurrence after permanent prostate brachytherapy in prostate cancer. Urology 2001; 58: 3939.
  • 14
    Shavers VL, Brown ML. Racial and ethnic disparities in the receipt of cancer treatment. J Natl Cancer Inst 2002; 94: 33457.
  • 15
    Vicini FA, Martinez A, Hanks G, Hanlon A, Miles B, Kernan K, Beyers D, Ragde H, Forman J, Fontanesi J, Kestin L, Kovacs G, et al. An interinstitutional and interspecialty comparison of treatment outcome data for patients with prostate carcinoma based on predefined prognostic categories and minimum follow-up. Cancer 2002; 95: 212635.
  • 16
    Ren F, Zhang S, Mitchell SH, Butler R, Young CY. Tea polyphenols down-regulate the expression of the androgen receptor in LNCaP prostate cancer cells. Oncogene 2000; 19: 192432.
  • 17
    Weisburger JH, Chung FL. Mechanisms of chronic disease causation by nutritional factors and tobacco products and their prevention by tea polyphenols. Food Chem Toxicol 2002; 40: 114554.
  • 18
    Lin JK. Cancer chemoprevention by tea polyphenols through modulating signal transduction pathways. Arch Pharm Res 2002; 25: 56171.
  • 19
    Ji BT, Chow WH, Hsing AW, McLaughlin JK, Dai Q, Gao YT, Blot WJ, Fraumeni JF Jr. Green tea consumption and the risk of pancreatic and colorectal cancers. Int J Cancer 1997; 70: 2558.
  • 20
    Weisburger J. Tea plant (Thea sinensis) and cancer. Cancer Res 1998: 58p.
  • 21
    Hakim IA, Harris RB, Weisgerber UM. Tea intake and squamous cell carcinoma of the skin: influence of type of tea beverages. Cancer Epidemiol Biomarkers Prev 2000; 9: 72731.
  • 22
    Inoue M, Tajima K, Hirose K, Hamajima N, Takezaki T, Kuroishi T, Tominaga S. Tea and coffee consumption and the risk of digestive tract cancers: data from a comparative case-referent study in Japan. Cancer Causes Control 1998; 9: 20916.
  • 23
    FAO. FAOSTAT, vol. 2001. Food and Agriculture Organization of The United Nations, 2001.
  • 24
    Zhou T. The total production of tea reached the highest level in Zhejiang province, vol. 2003. Zhejiang Provincial Bureau of Statistics, 2003.
  • 25
    Slattery ML, West DW. Smoking, alcohol, coffee, tea, caffeine, and theobromine: risk of prostate cancer in Utah (United States). Cancer Causes Control 1993; 4: 55963.
  • 26
    Jain MG, Hislop GT, Howe GR, Burch JD, Ghadirian P. Alcohol and other beverage use and prostate cancer risk among Canadian men. Int J Cancer 1998; 78: 70711.
  • 27
    Ellison LF. Tea and other beverage consumption and prostate cancer risk: a Canadian retrospective cohort study. Eur J Cancer Prev 2000; 9: 12530.
  • 28
    Zhang M, Binns CW, Lee AH. Tea consumption and ovarian cancer risk: a case-control study in China. Cancer Epidemiol Biomarkers Prev 2002; 11: 7138.
  • 29
    Thompson FE, Byers T. Dietary assessment resource manual. J Nutr 1994; 124: 2245S317S.
  • 30
    Australian Bureau of Statistics. National Health Survey 1995: summary of results. Australian Bureau of Statistics, 1995.
  • 31
    National Information Services. Food Questionnaire. National Information Services (NIS), 1992.
  • 32
    Ainsworth BE, Haskell WL, Whitt MC, Irwin ML, Swartz AM, Strath SJ, O'Brien WL, Bassett DR Jr., Schmitz KH, Emplaincourt PO, Jacobs DR Jr., Leon AS. Compendium of physical activities: an update of activity codes and MET intensities. Med Sci Sports Exerc 2000; 32: S498504.
  • 33
    Lacey JV, Jr., Deng J, Dosemeci M, Gao YT, Mostofi FK, Sesterhenn IA, Xie T, Hsing AW. Prostate cancer, benign prostatic hyperplasia and physical activity in Shanghai, China. Int J Epidemiol 2001; 30: 3419.
  • 34
    Institute of Nutrition & Food Health Academy of Chinese Preventive Medicine. Food Composition Tables. Beijing: People's Hygiene Press, 2000. 183 p.
  • 35
    Breslow RA, Wideroff L, Graubard BI, Erwin D, Reichman ME, Ziegler RG, Ballard-Barbash R. Alcohol and prostate cancer in the NHANES I epidemiologic follow-up study. First National Health and Nutrition Examination Survey of the United States. Ann Epidemiol 1999; 9: 25461.
  • 36
    Gupta S, Hastak K, Ahmad N, Lewin JS, Mukhtar H. Inhibition of prostate carcinogenesis in TRAMP mice by oral infusion of green tea polyphenols. Proc Natl Acad Sci USA 2001; 98: 103505.
  • 37
    Wang SI, Mukhtar H. Gene expression profile in human prostate LNCaP cancer cells by (−) epigallocatechin-3-gallate. Cancer Lett 2002; 182: 4351.
  • 38
    Kazi A, Smith DM, Zhong Q, Dou QP. Inhibition of bcl-x(l) phosphorylation by tea polyphenols or epigallocatechin-3-gallate is associated with prostate cancer cell apoptosis. Mol Pharmacol 2002; 62: 76571.
  • 39
    Nakachi K, Imai K, Suga K. Epidemiological evidence for prevention of cancer and cardiovascular disease by drinking green tea. In: YoshikawaT, ed. Food factors for cancer prevention. Tokyo: Springer-Verlag, 1997: 105-08.
  • 40
    Shi HG. Photograph of Chinese famous tea (green tea section), 2nd ed. Shanghai: Shanghai Culture Press, 1997. 3839.